{"id":"https://openalex.org/W2805202240","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.370","title":"Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)","display_name":"Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)","publication_year":2018,"publication_date":"2018-04-10","ids":{"openalex":"https://openalex.org/W2805202240","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.370","mag":"2805202240"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.90.15_supplement.p5.370","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.370","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.90.15_supplement.p5.370","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112195496","display_name":"Stuart D. Cook","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stuart Cook","raw_affiliation_strings":["Rutgers, the State University of New Jersey Newark NJ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rutgers, the State University of New Jersey Newark NJ United States","institution_ids":["https://openalex.org/I102322142"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043499649","display_name":"G\u0131ancarlo Com\u0131","orcid":"https://orcid.org/0000-0002-6989-1054","observed_orcids":["https://orcid.org/0000-0002-6989-1054"]},"institutions":[{"id":"https://openalex.org/I154387261","display_name":"Vita-Salute San Raffaele University","ror":"https://ror.org/01gmqr298","country_code":"IT","type":"education","lineage":["https://openalex.org/I154387261"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giancarlo Comi","raw_affiliation_strings":["Department of Neurology and Institute of Experimental Neurology, Universit\u00e0 Vita-Salute San Raffaele Milan Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology and Institute of Experimental Neurology, Universit\u00e0 Vita-Salute San Raffaele Milan Italy","institution_ids":["https://openalex.org/I154387261"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015754502","display_name":"Gavin Giovannoni","orcid":"https://orcid.org/0000-0001-9995-1700","observed_orcids":["https://orcid.org/0000-0001-9995-1700"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gavin Giovannoni","raw_affiliation_strings":["Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Peter Rieckmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I181369854","display_name":"Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","ror":"https://ror.org/00f7hpc57","country_code":"DE","type":"education","lineage":["https://openalex.org/I181369854"]},{"id":"https://openalex.org/I4210088053","display_name":"Universit\u00e4tsklinikum Erlangen","ror":"https://ror.org/0030f2a11","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210088053"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Peter Rieckmann","raw_affiliation_strings":["Department of Neurology, Medical Park Loipl and University of Erlangen Erlangen Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Medical Park Loipl and University of Erlangen Erlangen Germany","institution_ids":["https://openalex.org/I181369854","https://openalex.org/I4210088053"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062289553","display_name":"Per Soelberg Soerensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145217","display_name":"Danish Multiple Sclerosis Center","ror":"https://ror.org/04anq5q02","country_code":"DK","type":"facility","lineage":["https://openalex.org/I124055696","https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145217","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Per Soelberg Soerensen","raw_affiliation_strings":["Danish Multiple Sclerosis Center Copenhagen Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Danish Multiple Sclerosis Center Copenhagen Denmark","institution_ids":["https://openalex.org/I4210145217"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025462803","display_name":"Patrick Vermersch","orcid":"https://orcid.org/0000-0003-0997-8817","observed_orcids":["https://orcid.org/0000-0003-0997-8817"]},"institutions":[{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Patrick Vermersch","raw_affiliation_strings":["Universit\u00e9 de Lille Lillie France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 de Lille Lillie France","institution_ids":["https://openalex.org/I2279609970"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010771032","display_name":"Fernando Dangond","orcid":"https://orcid.org/0000-0002-6723-4229","observed_orcids":["https://orcid.org/0000-0002-6723-4229"]},"institutions":[{"id":"https://openalex.org/I4210111614","display_name":"EMD Serono, Inc. (United States)","ror":"https://ror.org/027zrs220","country_code":"US","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4210111614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fernando Dangond","raw_affiliation_strings":["EMD Serono, Inc. Billerica MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Inc. Billerica MA United States","institution_ids":["https://openalex.org/I4210111614"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000898624","display_name":"Christine Hicking","orcid":"https://orcid.org/0009-0002-7750-8892","observed_orcids":["https://orcid.org/0009-0002-7750-8892"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Christine Hicking","raw_affiliation_strings":["Merck KGaA Darmstadt Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck KGaA Darmstadt Germany","institution_ids":["https://openalex.org/I164928964"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0727025,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"90","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.5952000021934509,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.5952000021934509,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.3296000063419342,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cladribine-tablets","display_name":"cladribine tablets","score":0.871999979019165},{"id":"https://openalex.org/keywords/lymphopenia","display_name":"lymphopenia","score":0.7540000081062317},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.7639999985694885}],"concepts":[{"id":"https://openalex.org/C2779200787","wikidata":"https://www.wikidata.org/wiki/Q414030","display_name":"Cladribine","level":2,"score":0.8561916947364807},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.747447669506073},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.726606547832489},{"id":"https://openalex.org/C2777761686","wikidata":"https://www.wikidata.org/wiki/Q715347","display_name":"Lymphocyte","level":2,"score":0.4837908446788788},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3239176571369171},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.06047588586807251},{"id":"https://openalex.org/C2524010","wikidata":"https://www.wikidata.org/wiki/Q8087","display_name":"Geometry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.90.15_supplement.p5.370","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.370","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.90.15_supplement.p5.370","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2890583582","https://openalex.org/W2771900644","https://openalex.org/W4389436972","https://openalex.org/W2790581926","https://openalex.org/W2891505869","https://openalex.org/W2887988637","https://openalex.org/W3200379281","https://openalex.org/W2149420411","https://openalex.org/W1631077610","https://openalex.org/W1988446588"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"evaluate":[2],"whether":[3],"lymphopenia":[4,83,98,134,160,194,218,267,278,297],"persists":[5],"following":[6],"treatment":[7,224,273,299],"and":[8,62,93,119,147,151,167,175,180,201,243,275,338,383,385,456,490,519,536],"re-treatment":[9,232,288],"with":[10,53,80,300,326,366,442,479,510,556,578],"cladribine":[11],"tablets":[12],"(CT)":[13],"3.5":[14,55,64],"mg/kg.":[15],"Background:":[16],"In":[17,227],"CLARITY,":[18],"the":[19,58,67,88,115,127,220,240,269,284,292],"CT":[20,54,63,92,255],"group":[21],"(3.5":[22],"mg/kg)":[23],"demonstrated":[24],"lower":[25],"annualized":[26],"relapse":[27],"rates":[28],"versus":[29],"placebo":[30],"(0.14":[31],"vs.":[32],"0.33;":[33],"P<0.001)":[34],"at":[35,114,126,141,153,208,219,268],"96":[36],"weeks":[37],"(wks).":[38],"The":[39],"most":[40],"common":[41],"adverse":[42],"event":[43],"was":[44,135,161,195,202,279],"lymphopenia.":[45],"Design/Methods:":[46],"Lymphopenia":[47],"by":[48,169,182],"grade":[49],"for":[50,314,354,369,410,430,467,498,544,566],"patients":[51,110,140,207,214,228,263],"treated":[52,229],"mg/kg":[56,65,73,259],"in":[57,66,137,143,148,155,163,171,176,184,189,198,204,290,374,406],"2-year":[59,68],"CLARITY":[60,69,118,130],"study":[61,71],"Extension":[70],"(7":[72],"cumulative":[74,260],"dose;":[75],"N=186)":[76],"are":[77],"reported.":[78],"Patients":[79],"Grade":[81,94,112,122,132,158,192,216,265,276],"0":[82,95,113,123],"(\u22651.0\u00d710":[84],"9":[85,100,237,245],"cells/L)":[86,101],"before":[87,102,239,247],"first":[89,241],"course":[90,242],"of":[91,117,129,139,173,206,222,254,271,286,294,414],"or":[96,124,323,363,439,476,507,553,575],"1":[97,125],"(\u22650.8\u00d710":[99],"all":[103],"subsequent":[104,251],"courses":[105,253],"were":[106,111,121],"included.":[107],"Results:":[108],"176":[109],"start":[116,128],"167":[120],"Extension.":[131],"3":[133,159,193,250,277],"observed":[136,162,197],"1%":[138],"Wk13":[142],"Year":[144],"(Y)":[145],"1,":[146],"7%,":[149],"11%,":[150],"12%":[152],"Wk12":[154],"Y2\u20134,":[156],"respectively.":[157],"1%,":[164,177],"4%,":[165,166],"4%":[168],"Wk24":[170],"each":[172,185,190],"Y1\u20134,":[174],"2%,":[178,179],"2%":[181],"Wk36":[183],"year.":[186,225],"By":[187],"Wk48":[188],"year,":[191,274],"only":[196],"Y2":[199],"(1%),":[200],"reported":[203],"<18%":[205],"any":[209,223,272],"single":[210],"time":[211],"point.":[212],"No":[213],"had":[215],"4":[217,266],"end":[221,270],"Conclusions:":[226],"according":[230],"to":[231,249,257,346,376],"guidelines":[233],"(lymphocyte":[234],"counts":[235],"\u22651.0\u00d710":[236],"/L":[238,246],"\u22650.8\u00d710":[244],"up":[248],"annual":[252],"[up":[256],"7":[258],"dose]),":[261],"no":[262],"experienced":[264],"uncommon.":[280],"These":[281],"results":[282],"demonstrate":[283],"effectiveness":[285],"lymphocyte-based":[287],"criteria":[289],"minimizing":[291],"incidence":[293],"severe,":[295],"sustained":[296],"during":[298],"CT.":[301],"Study":[302],"Supported":[303],"by:":[304],"EMD":[305,557],"Serono":[306,457],"Disclosure:":[307],"Dr.":[308,342,348,400,416,424,461,492,521,538,560],"Cook":[309],"has":[310,344,350,402,418,426,463,494,523,540,562],"received":[311,351,403,419,427,464,495,524,541,563],"personal":[312,352,404,428,465,496,542,564],"compensation":[313,353,368,405,429,466,497,543,565],"consulting,":[315,355,431,468,499,545,567],"serving":[316,356,432,469,500,546,568],"on":[317,357,371,433,470,501,547,569],"a":[318,358,434,471,502,548,570],"scientific":[319,359,435,472,503,549,571],"advisory":[320,360,436,473,504,550,572],"board,":[321,361,437,474,505,551,573],"speaking,":[322,362,438,475,506,552,574],"other":[324,364,440,477,508,554,576],"activities":[325,365,441,478,509,555,577],"Merck":[327,579],"Serono,":[328,558],"Bayer":[329,446],"HealthCare,":[330],"Sanofi-Aventis,":[331,450],"Neurology":[332],"Reviews,":[333],"Biogen":[334,444],"Idec,":[335,445],"Teva":[336,453],"Pharmaceuticals,":[337,486],"Actinobac":[339],"Biomed":[340],"Inc.":[341,559],"Comi":[343],"nothing":[345],"disclose.":[347],"Giovannoni":[349,401,417],"Received":[367],"participating":[370],"Advisory":[372],"Boards":[373],"relation":[375],"clinical":[377],"trial":[378,380],"design,":[379],"steering":[381],"committees":[382,388],"data":[384],"safety":[386],"monitoring":[387],"from:":[389],"Abbvie,":[390],"Almirall,":[391,511,528],"Atara":[392],"Bio,":[393],"Biogen,":[394,481,512,529],"Sanofi-Genzyme,":[395],"Genentech,":[396],"GSK,":[397,484],"Merck,":[398,443,480,514,531],"Novartis.":[399],"an":[407],"editorial":[408],"capacity":[409],"Elsevier":[411],"as":[412],"Editor":[413],"MSARDs.":[415],"research":[420,525],"support":[421,526],"from":[422,527],"Takeda.":[423],"Rieckmann":[425],"Schering":[447],"Pharma,":[448],"Boehringer-Ingelheim,":[449],"Genzyme,":[451],"Novartis,":[452,482,515,532],"Pharmaceutical":[454],"Industries,":[455],"Symposia":[458],"International":[459],"Foundation.":[460],"Soerensen":[462],"Teva,":[483],"MedDay":[485],"Celgene,":[487,513,530],"Forward":[488],"Pharma":[489],"Sanofi/Genzyme.":[491],"Vermersch":[493,522],"Roche,":[516,533],"Sanofi,":[517,534],"Servier,":[518,535],"Teva.":[520,537],"Dangond":[539],"Hicking":[561],"KGaA.":[580]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-06-13T00:00:00"}